Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T9HG
|
|||
| Former ID |
DNC003010
|
|||
| Drug Name |
GM6001
|
|||
| Synonyms |
Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup; ILOMASTAT
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Corneal ulcer [ICD-11: 9A76; ICD-10: H16.0; ICD-9: 370] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H28N4O4
|
|||
| Canonical SMILES |
CC(C)CC(CC(=O)NO)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC
|
|||
| InChI |
1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1
|
|||
| InChIKey |
NITYDPDXAAFEIT-DYVFJYSZSA-N
|
|||
| CAS Number |
CAS 142880-36-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
829892, 10243138, 11120050, 11120538, 11121026, 11121715, 11122195, 11147133, 11362833, 11365395, 11367957, 11370897, 11370898, 11373558, 11376119, 12014779, 14878422, 14902905, 17397881, 24902217, 26756835, 26758815, 29310648, 46484604, 46506673, 47364924, 47588747, 48034840, 48258955, 48427395, 50070501, 50071141, 50111444, 50111445, 53790355, 57344178, 79412811, 81060888, 81062449, 81062451, 92310066, 99029951, 99300978, 99302498, 103185416, 103957874, 104377641, 121379601, 124892442, 134340919
|
|||
| ChEBI ID |
CHEBI:137236
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001387) | |||
| REF 2 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
| REF 3 | Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. | |||
| REF 4 | Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. | |||
| REF 5 | Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91. | |||
| REF 6 | Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats. Scand J Gastroenterol. 2006 Nov;41(11):1320-9. | |||
| REF 7 | Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol. 2008 Apr;28(7):2391-413. | |||
| REF 8 | Hydroxamate inhibitors of human gelatinase B (92 kDa), Bioorg. Med. Chem. Lett. 5(4):349-352 (1995). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.